Surgery for thyroid Hürthle cell tumours—a single institution experience

Paunović, Ivan; Krgović, K; Tatic, Svetislav; Diklić, Aleksandar; Živaljević, Vladan; Kalezić, Nevena; Havelka, M

doi:10.1016/j.ejso.2005.11.023

Cited by 18 publications

(16 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, there are disagreements regarding the age difference between the Hurthle cell adenoma and Hurthle cell carcinoma. Study of Barnabei et al and one study from our center showed that there was no difference regarding age (49 years), while study of Lopez-Penabad et al showed that patients with Hurthle cell carcinoma are older at the time of surgery than patients with Hurthle cell adenomas, 51.8 years vs. 43.1 years [12–14]. …”

Section: Discussionmentioning

confidence: 99%

Survival and prognostic factors for survival, cancer specific survival and disease free interval in 239 patients with Hurthle cell carcinoma: a single center experience

Oluić¹,

Paunović²,

Lončar³

et al. 2017

BMC Cancer

View full text Add to dashboard Cite

BackgroundHurthle cell carcinoma makes up 3 to 5% of all thyroid cancers and is considered to be a true rarity. The aim of our study was to analyze clinical characteristics and survival rates of patients with Hurthle cell carcinoma.MethodsClinical data regarding basic demographic characteristics, tumor grade, type of surgical treatment and vital status were collected. Methods of descriptive statistics and Kaplan-Meier survival curves were used for statistical analysis. Cox proportional hazards regression was used to identify independent predictors.ResultsDuring the period from 1995 to 2014, 239 patients with Hurthle cell carcinoma were treated at our Institution. The average age of the patients was 54.3, with female to male ratio of 3.6:1 and average tumor size was 41.8 mm. The overall recurrence rate was 12.1%, with average time for relapse of 90.74 months and average time without any signs of the disease of 222.4 months. Overall 5-year, 10-year and 20-year survival rates were 89.4%, 77.2%, 61.9% respectively. The 5-year, 10-year and 20-year cancer specific survival rates were 94.6%, 92.5%, 87.4%, respectively. When disease free interval was observed, 5-year, 10-year and 20-year rates were 91.1%, 86.2%, 68.5%, respectively. The affection of both thyroid lobes and the need for reoperation due to local relapse were unfavorable independent prognostic factors, while total thyroidectomy as primary procedure was favorable predictive factor for cancer specific survival.ConclusionHurthle cell carcinoma is a rare tumor with an encouraging prognosis and after adequate surgical treatment recurrences are rare.

show abstract

Section: Discussionmentioning

confidence: 99%

Survival and prognostic factors for survival, cancer specific survival and disease free interval in 239 patients with Hurthle cell carcinoma: a single center experience

Oluić¹,

Paunović²,

Lončar³

et al. 2017

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Several authors have observed an association between tumor size and the rate of cancer, 2,4,11,19–26 while others have not found this association to be significant. 27–31 In our series, on average, HCCs were significantly larger than HCAs (4.50 cm versus 2.46 cm).…”

Section: Discussionmentioning

confidence: 99%

Older Age and Larger Tumor Size Predict Malignancy in Hürthle Cell Neoplasms of the Thyroid

et al. 2008

View full text Add to dashboard Cite

Background Hürthle cell neoplasms (HCNs) are rare tumors of the thyroid gland. The definitive treatment for Hürthle cell carcinoma (HCC) is total thyroidectomy, while thyroid lobectomy is adequate for Hürthle cell adenoma (HCA). However, differentiating HCC from HCA either before or during surgery is a challenge. The purpose of this study was to identify factors that predict malignancy in patients with HCN. Methods Between May 1994 and January 2007, 1,199 patients underwent thyroid surgery at an academic medical center. Medical records of 55 consecutive patients who underwent thyroid resections for the preoperative diagnosis of HCN were reviewed. Results Of the 55 patients with HCN, 46 (84%) had adenomas and 9 (16%) had carcinomas. Patients with HCC were significantly older than those with HCA (66 ± 6 years versus 53 ± 2 years, P = 0.01). Patients with carcinoma also had significantly larger thyroid nodules (4.5 ± 0.7 cm versus 2.5 ± 0.2 cm, P < 0.001). All HCNs less than 2 cm in diameter were benign. The malignancy rate increased with nodule size: 18% of nodules measuring 2–4 cm, and 44% of those larger than 4 cm were HCC. One patient with HCC had recurrence of the disease, but there were no disease-related deaths. Conclusion Advanced patient age and larger nodule size are two important factors that predict malignancy in patients with HCN. In patients with these and other known risk factors for HCC, total thyroidectomy should be considered.

show abstract

“…Les COT relèvent d'une thyroïdectomie totale qui sera effectuée soit d'emblée lorsque le diagnostic de malignité est affirmé à la cytoponction et à l'examen extemporanné, soit dans un deuxième temps si le diagnostic de COT est révélé à l'examen histologique définitif. L'éxérèse des ganglions récurrentiels et jugulo-carotidiens est indiquée en cas d'adénopathies métastatiques (11,12,13). Le traitement par l'iode radioactif améliore le pronostic des COT s'il est administré de façon systématique et non pas uniquement en cas de présence de résidu tumoral (1,6,10,12,13).…”

Section: Discussionunclassified

“…L'éxérèse des ganglions récurrentiels et jugulo-carotidiens est indiquée en cas d'adénopathies métastatiques (11,12,13). Le traitement par l'iode radioactif améliore le pronostic des COT s'il est administré de façon systématique et non pas uniquement en cas de présence de résidu tumoral (1,6,10,12,13). En effet, ce type de tumeurs n'est pas trés sensible à l'iode radioactif.…”

Section: Discussionunclassified